Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial

Background & Aims Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. Methods We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral...

Full description

Saved in:
Bibliographic Details
Published inClinical gastroenterology and hepatology Vol. 8; no. 5; pp. 458 - 462
Main Authors Delgado–Borrego, Aymin, Jordan, Sergio H, Negre, Betania, Healey, David, Lin, Wenyu, Kamegaya, Yoshitaka, Christofi, Marielle, Ludwig, David A, Lok, Anna S.F, Chung, Raymond T
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background & Aims Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. Methods We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial to evaluate whether suppression of hepatitis C is associated with improvement in IR. Participants had advanced hepatic fibrosis and carried non-3 HCV genotypes (n = 96). Patients underwent 24 weeks of pegylated interferon and ribavirin therapy and were categorized into HCV clearance groups at week 20 on the basis of HCV RNA levels; null responders had <1 log10 decline (n = 38), partial responders had ≥1 log10 decline (n = 37) but detectable HCV RNA, and complete responders had no detectable HCV RNA (n = 21). The primary outcome was change (week 20 minus week 0) in IR by using the homeostasis model assessment (HOMA2-IR). Results Adjusting only for baseline HOMA2-IR, mean HOMA2-IR differences were −2.23 (complete responders), −0.90 (partial responders), and +0.18 (null responders) ( P = .036). The observed differences in mean HOMA2-IR scores were ordered in a linear fashion across response groups ( P = .01). The association between HCV clearance and improvement in HOMA2-IR could not be accounted for by adiponectin or tumor necrosis factor–alpha and was independent of potential confounders including age, gender, ethnicity, body mass index, duration of infection, medications used, and fibrosis. Conclusions HCV suppression correlates with improvement in IR. These data provide further support for a role of HCV in the development of insulin resistance.
AbstractList Background & Aims Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. Methods We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial to evaluate whether suppression of hepatitis C is associated with improvement in IR. Participants had advanced hepatic fibrosis and carried non-3 HCV genotypes (n = 96). Patients underwent 24 weeks of pegylated interferon and ribavirin therapy and were categorized into HCV clearance groups at week 20 on the basis of HCV RNA levels; null responders had <1 log10 decline (n = 38), partial responders had ≥1 log10 decline (n = 37) but detectable HCV RNA, and complete responders had no detectable HCV RNA (n = 21). The primary outcome was change (week 20 minus week 0) in IR by using the homeostasis model assessment (HOMA2-IR). Results Adjusting only for baseline HOMA2-IR, mean HOMA2-IR differences were −2.23 (complete responders), −0.90 (partial responders), and +0.18 (null responders) ( P = .036). The observed differences in mean HOMA2-IR scores were ordered in a linear fashion across response groups ( P = .01). The association between HCV clearance and improvement in HOMA2-IR could not be accounted for by adiponectin or tumor necrosis factor–alpha and was independent of potential confounders including age, gender, ethnicity, body mass index, duration of infection, medications used, and fibrosis. Conclusions HCV suppression correlates with improvement in IR. These data provide further support for a role of HCV in the development of insulin resistance.
Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial to evaluate whether suppression of hepatitis C is associated with improvement in IR. Participants had advanced hepatic fibrosis and carried non-3 HCV genotypes (n = 96). Patients underwent 24 weeks of pegylated interferon and ribavirin therapy and were categorized into HCV clearance groups at week 20 on the basis of HCV RNA levels; null responders had <1 log 10 decline (n = 38), partial responders had ≥1 log 10 decline (n = 37) but detectable HCV RNA, and complete responders had no detectable HCV RNA (n = 21). The primary outcome was change (week 20 minus week 0) in IR by using the homeostasis model assessment (HOMA2-IR). Adjusting only for baseline HOMA2-IR, mean HOMA2-IR differences were −2.23 (complete responders), −0.90 (partial responders), and +0.18 (null responders) ( P = .036). The observed differences in mean HOMA2-IR scores were ordered in a linear fashion across response groups ( P = .01). The association between HCV clearance and improvement in HOMA2-IR could not be accounted for by adiponectin or tumor necrosis factor–alpha and was independent of potential confounders including age, gender, ethnicity, body mass index, duration of infection, medications used, and fibrosis. HCV suppression correlates with improvement in IR. These data provide further support for a role of HCV in the development of insulin resistance.
Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has not been established. We performed a longitudinal study within the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial to evaluate whether suppression of hepatitis C is associated with improvement in IR. Participants had advanced hepatic fibrosis and carried non-3 HCV genotypes (n = 96). Patients underwent 24 weeks of pegylated interferon and ribavirin therapy and were categorized into HCV clearance groups at week 20 on the basis of HCV RNA levels; null responders had <1 log(10) decline (n = 38), partial responders had >or=1 log(10) decline (n = 37) but detectable HCV RNA, and complete responders had no detectable HCV RNA (n = 21). The primary outcome was change (week 20 minus week 0) in IR by using the homeostasis model assessment (HOMA2-IR). Adjusting only for baseline HOMA2-IR, mean HOMA2-IR differences were -2.23 (complete responders), -0.90 (partial responders), and +0.18 (null responders) (P = .036). The observed differences in mean HOMA2-IR scores were ordered in a linear fashion across response groups (P = .01). The association between HCV clearance and improvement in HOMA2-IR could not be accounted for by adiponectin or tumor necrosis factor-alpha and was independent of potential confounders including age, gender, ethnicity, body mass index, duration of infection, medications used, and fibrosis. HCV suppression correlates with improvement in IR. These data provide further support for a role of HCV in the development of insulin resistance.
Author Jordan, Sergio H
Lin, Wenyu
Kamegaya, Yoshitaka
Lok, Anna S.F
Negre, Betania
Ludwig, David A
Christofi, Marielle
Chung, Raymond T
Delgado–Borrego, Aymin
Healey, David
AuthorAffiliation 2 Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
3 Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI
1 Department of Pediatrics, Batchelor Children’s Research Institute, University of Miami, Miami, FL 33136
AuthorAffiliation_xml – name: 2 Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
– name: 3 Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI
– name: 1 Department of Pediatrics, Batchelor Children’s Research Institute, University of Miami, Miami, FL 33136
Author_xml – sequence: 1
  fullname: Delgado–Borrego, Aymin
– sequence: 2
  fullname: Jordan, Sergio H
– sequence: 3
  fullname: Negre, Betania
– sequence: 4
  fullname: Healey, David
– sequence: 5
  fullname: Lin, Wenyu
– sequence: 6
  fullname: Kamegaya, Yoshitaka
– sequence: 7
  fullname: Christofi, Marielle
– sequence: 8
  fullname: Ludwig, David A
– sequence: 9
  fullname: Lok, Anna S.F
– sequence: 10
  fullname: Chung, Raymond T
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20156586$$D View this record in MEDLINE/PubMed
BookMark eNp9kdtqGzEURUVJaS7tB_Sl6AfsHmk0txYCYUjqgKGQuvRRyNJRLHcsGWnGkL-vJk5Dk4c-6XL23kJrn5MTHzwS8pHBnAGrPm_n-n4z55DPwObA-RtyxkrBZ3XNxMnTviir8pScp7QF4K1o63fkNFvybVOdkf0dmlEPLngaLL31aeydp3eYXBqU10h_uWFDr63FLDog7XpU8XGQ5Qvcq8ENLtEuWx8lwX-Z3GM_JHoTw44OG6SLq-Vq1tFVdKp_T95a1Sf88LRekJ8316tuMVt-_3bbXS1nuoRymNWqWNcNt40pTcNbrGxjNTNGaGsKARVTlqlSoFivURlgFhpooW1sJThaKIoLcnnM3Y_rHRqNfoiql_vodio-yKCcfDnxbiPvw0HypqzqYgpgxwAdQ0oR7bOXgZzwy63M-OWEXwKTGX_2fPr30WfHX95Z8PUowPz1g8Mok3aYcRoXMz5pgvtv_OUrt85tOa363_iAaRvG6DNTyWTiEuSPqf-pfgYATIim-ANxe63S
CitedBy_id crossref_primary_10_1016_j_jhep_2011_03_010
crossref_primary_10_1016_j_kjms_2012_11_001
crossref_primary_10_1016_j_dld_2010_12_011
crossref_primary_10_1053_j_gastro_2018_10_033
crossref_primary_10_1186_s43066_020_00061_9
crossref_primary_10_1002_cld_694
crossref_primary_10_1016_j_gtc_2020_01_007
crossref_primary_10_1016_j_jare_2016_11_003
crossref_primary_10_1093_cid_cir076
crossref_primary_10_1016_j_jsps_2021_08_006
crossref_primary_10_1002_jmv_24897
crossref_primary_10_1111_jvh_12408
crossref_primary_10_1016_j_jhepr_2019_11_001
crossref_primary_10_3390_v16030371
crossref_primary_10_1016_j_dld_2015_10_016
crossref_primary_10_1111_jvh_13215
crossref_primary_10_1080_19932820_2018_1435124
crossref_primary_10_1111_jgh_14067
crossref_primary_10_3892_etm_2019_7995
crossref_primary_10_1515_tjb_2018_0163
crossref_primary_10_1007_s00535_012_0669_x
crossref_primary_10_1097_MPG_0b013e318258328d
crossref_primary_10_1111_liv_13669
crossref_primary_10_1089_jir_2014_0200
crossref_primary_10_1586_egh_11_43
crossref_primary_10_18553_jmcp_2020_26_6_775
crossref_primary_10_1371_journal_pone_0020922
crossref_primary_10_1007_s11739_019_02163_8
crossref_primary_10_1016_j_jhep_2011_02_004
crossref_primary_10_1016_j_yapd_2016_04_019
crossref_primary_10_3389_fendo_2021_799382
crossref_primary_10_1080_07853890_2023_2168745
crossref_primary_10_4254_wjh_v8_i35_1557
crossref_primary_10_1111_j_1600_6143_2011_03843_x
crossref_primary_10_1371_journal_pone_0209216
crossref_primary_10_1007_s11154_018_9475_y
crossref_primary_10_1093_cid_cis463
crossref_primary_10_2337_dc17_0485
crossref_primary_10_1016_j_aidm_2014_12_003
crossref_primary_10_1002_jmv_24954
crossref_primary_10_1186_s43066_021_00136_1
crossref_primary_10_1002_jgh3_12474
crossref_primary_10_3350_cmh_2014_20_1_38
crossref_primary_10_5812_hepatmon_58022
crossref_primary_10_4254_wjh_v3_i5_99
crossref_primary_10_1016_j_ejim_2023_05_005
crossref_primary_10_1080_21505594_2017_1300734
crossref_primary_10_1111_j_1872_034X_2011_00833_x
crossref_primary_10_1155_2015_975695
crossref_primary_10_17116_terarkh20168811138_148
crossref_primary_10_1097_MPG_0000000000000604
crossref_primary_10_1111_imj_12136
crossref_primary_10_1002_hep_25661
crossref_primary_10_1016_j_jfma_2020_08_033
crossref_primary_10_4103_ijmr_IJMR_1088_18
crossref_primary_10_1007_s00592_018_1257_1
crossref_primary_10_1016_j_gtc_2015_07_003
Cites_doi 10.1210/jcem-44-4-681
10.1016/j.jhep.2004.03.020
10.1002/lt.21267
10.1016/S0002-9440(10)63408-6
10.1309/42D6-W7PL-FX0A-LBXF
10.1002/hep.21265
10.1016/j.jhep.2008.08.006
10.1097/01.TP.0000114283.04840.3A
10.1053/j.gastro.2004.12.049
10.1152/ajpendo.00494.2003
10.1053/j.gastro.2003.08.032
10.1128/JCM.41.2.651-656.2003
10.1111/j.1365-2796.2005.01543.x
10.2337/diacare.27.6.1487
10.1016/j.cct.2004.08.003
10.1053/j.gastro.2003.11.056
10.1016/j.cgh.2006.11.002
10.1111/j.1572-0241.2006.01038.x
ContentType Journal Article
Copyright AGA Institute
2010 AGA Institute
Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: AGA Institute
– notice: 2010 AGA Institute
– notice: Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
CorporateAuthor Halt–C Trial Group
Halt-C Trial Group
CorporateAuthor_xml – name: Halt–C Trial Group
– name: Halt-C Trial Group
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.1016/j.cgh.2010.01.022
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1542-7714
EndPage 462
ExternalDocumentID 10_1016_j_cgh_2010_01_022
20156586
S1542356510001448
1_s2_0_S1542356510001448
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: Robert Wood Johnson Foundation
– fundername: NIH
  grantid: K08 DK070022
– fundername: NIH
  grantid: P60 DK020572
– fundername: NIH
  grantid: N01-DK-9-2323
– fundername: NIH
  grantid: DK078772
– fundername: NIDDK NIH HHS
  grantid: P60 DK020572
– fundername: NIDDK NIH HHS
  grantid: DK078772
– fundername: NIDDK NIH HHS
  grantid: K08 DK070022-05
– fundername: NIDDK NIH HHS
  grantid: K24 DK078772-03
– fundername: NIDDK NIH HHS
  grantid: K08 DK070022
– fundername: NIDDK NIH HHS
  grantid: K24 DK078772
– fundername: NIDDK NIH HHS
  grantid: N01-DK-9-2323
GroupedDBID ---
--K
.1-
.FO
0R~
1B1
1CY
1P~
29B
4.4
457
53G
5GY
5VS
AAEDT
AAEDW
AALRI
AAQFI
AAQQT
AAXUO
ABJNI
ABLJU
ABMAC
ACGFS
ADBBV
ADPAM
AENEX
AEVXI
AFCTW
AFJKZ
AFRHN
AFTJW
AITUG
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BELOY
C45
C5W
CS3
DU5
EBS
EJD
F5P
FDB
FRP
HZ~
IHE
KOM
M41
MO0
N9A
NQ-
O9-
OBH
OC.
ON0
OVD
P2P
RIG
ROL
RPZ
SEL
SES
TEORI
UV1
XH2
Z5R
AAIAV
AGZHU
ALXNB
ZA5
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
ID FETCH-LOGICAL-c505t-7a3b782f8d5d829e6f8fc1dd4cfd34061af1a54e4bbead01f0809098f642ef033
ISSN 1542-3565
IngestDate Tue Sep 17 21:19:21 EDT 2024
Thu Sep 26 15:35:19 EDT 2024
Sat Sep 28 07:58:27 EDT 2024
Fri Feb 23 02:27:34 EST 2024
Tue Oct 15 22:57:17 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords HALT-C
body mass index
IR
TMA
Hepatitis C Antiviral Long-Term Treatment against Cirrhosis
AN
HOMA2-IR
transcription-mediated amplification
Adiponectin
Cirrhosis
TNF-α
tumor necrosis factor–α
HOMA
Interferon
insulin resistance
homeostasis model assessment
BMI
Language English
License Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c505t-7a3b782f8d5d829e6f8fc1dd4cfd34061af1a54e4bbead01f0809098f642ef033
Notes www.hatlctrial.org, Trial number: NCT00825877
OpenAccessLink http://www.cghjournal.org/article/S1542356510001448/pdf
PMID 20156586
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2856733
crossref_primary_10_1016_j_cgh_2010_01_022
pubmed_primary_20156586
elsevier_sciencedirect_doi_10_1016_j_cgh_2010_01_022
elsevier_clinicalkeyesjournals_1_s2_0_S1542356510001448
PublicationCentury 2000
PublicationDate 2010-05-01
PublicationDateYYYYMMDD 2010-05-01
PublicationDate_xml – month: 05
  year: 2010
  text: 2010-05-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical gastroenterology and hepatology
PublicationTitleAlternate Clin Gastroenterol Hepatol
PublicationYear 2010
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Shintani, Fujie, Miyoshi (bib7) 2004; 126
Kanai, Omata (bib19) 2005; 63
Hui, Sud, Farrell (bib4) 2003; 125
Kaser, Moschen, Kaser (bib18) 2005; 258
Delgado-Borrego, Liu, Jordan (bib5) 2008; 14
Wallace, Levy, Matthews (bib13) 2004; 27
Lee, Dienstag, Lindsay (bib8) 2004; 25
Narita, Abe, Kihara, Akiyama (bib1) 2004; 41
Delgado-Borrego, Casson, Schoenfeld (bib2) 2004; 77
Sasaoka (bib20) 2002; 60
Romero-Gomez, Del Mar Viloria, Andrade (bib15) 2005; 128
Lok, Everhart, Chung (bib9) 2007; 5
White, Ratziu, El-Serag (bib3) 2008; 49
Hendricks, Friesenhahn, Tanimoto (bib11) 2003; 41
Kawaguchi, Yoshida, Harada (bib6) 2004; 165
Kawaguchi, Ide, Taniguchi (bib16) 2007; 102
Morishima, Morgan, Everhart (bib14) 2006; 44
Hayashi, Floyd, Pek (bib12) 1977; 44
Tietge, Boker, Manns (bib17) 2004; 287
Ishak (bib10) 2000; 113
12238132 - Nihon Rinsho. 2002 Jul;60 Suppl 7:760-5
15465617 - Control Clin Trials. 2004 Oct;25(5):472-92
18236394 - Liver Transpl. 2008 Feb;14(2):193-201
10631857 - Am J Clin Pathol. 2000 Jan;113(1):40-55
3899825 - Diabetologia. 1985 Jul;28(7):412-9
15246219 - J Hepatol. 2004 Jul;41(1):132-8
16115302 - J Intern Med. 2005 Sep;258(3):274-80
15509521 - Am J Pathol. 2004 Nov;165(5):1499-508
17296533 - Clin Gastroenterol Hepatol. 2007 Feb;5(2):245-54
15765399 - Gastroenterology. 2005 Mar;128(3):636-41
15010338 - Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E82-9
12574262 - J Clin Microbiol. 2003 Feb;41(2):651-6
18814931 - J Hepatol. 2008 Nov;49(5):831-44
15779394 - Nihon Rinsho. 2005 Feb;63 Suppl 2:315-9
16614743 - Int J Med Sci. 2006;3(2):53-6
17222321 - Am J Gastroenterol. 2007 Mar;102(3):570-6
14988838 - Gastroenterology. 2004 Mar;126(3):840-8
14724822 - Gastroenterology. 2003 Dec;125(6):1695-704
16871570 - Hepatology. 2006 Aug;44(2):360-7
14970 - J Clin Endocrinol Metab. 1977 Apr;44(4):681-94
17596870 - Hepatology. 2007 Jul;46(1):66-73
15161807 - Diabetes Care. 2004 Jun;27(6):1487-95
15021833 - Transplantation. 2004 Mar 15;77(5):703-10
Narita (10.1016/j.cgh.2010.01.022_bib1) 2004; 41
Wallace (10.1016/j.cgh.2010.01.022_bib13) 2004; 27
Delgado-Borrego (10.1016/j.cgh.2010.01.022_bib2) 2004; 77
Hui (10.1016/j.cgh.2010.01.022_bib4) 2003; 125
Delgado-Borrego (10.1016/j.cgh.2010.01.022_bib5) 2008; 14
Romero-Gomez (10.1016/j.cgh.2010.01.022_bib15) 2005; 128
Tietge (10.1016/j.cgh.2010.01.022_bib17) 2004; 287
Kawaguchi (10.1016/j.cgh.2010.01.022_bib16) 2007; 102
Shintani (10.1016/j.cgh.2010.01.022_bib7) 2004; 126
Kanai (10.1016/j.cgh.2010.01.022_bib19) 2005; 63
Lee (10.1016/j.cgh.2010.01.022_bib8) 2004; 25
Kawaguchi (10.1016/j.cgh.2010.01.022_bib6) 2004; 165
Kaser (10.1016/j.cgh.2010.01.022_bib18) 2005; 258
White (10.1016/j.cgh.2010.01.022_bib3) 2008; 49
Hendricks (10.1016/j.cgh.2010.01.022_bib11) 2003; 41
Morishima (10.1016/j.cgh.2010.01.022_bib14) 2006; 44
Sasaoka (10.1016/j.cgh.2010.01.022_bib20) 2002; 60
Ishak (10.1016/j.cgh.2010.01.022_bib10) 2000; 113
Lok (10.1016/j.cgh.2010.01.022_bib9) 2007; 5
Hayashi (10.1016/j.cgh.2010.01.022_bib12) 1977; 44
References_xml – volume: 5
  start-page: 245
  year: 2007
  end-page: 254
  ident: bib9
  article-title: Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial
  publication-title: Clin Gastroenterol Hepatol
  contributor:
    fullname: Chung
– volume: 102
  start-page: 570
  year: 2007
  end-page: 576
  ident: bib16
  article-title: Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2
  publication-title: Am J Gastroenterol
  contributor:
    fullname: Taniguchi
– volume: 77
  start-page: 703
  year: 2004
  end-page: 710
  ident: bib2
  article-title: Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation
  publication-title: Transplantation
  contributor:
    fullname: Schoenfeld
– volume: 44
  start-page: 681
  year: 1977
  end-page: 694
  ident: bib12
  article-title: Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism
  publication-title: J Clin Endocrinol Metab
  contributor:
    fullname: Pek
– volume: 128
  start-page: 636
  year: 2005
  end-page: 641
  ident: bib15
  article-title: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
  publication-title: Gastroenterology
  contributor:
    fullname: Andrade
– volume: 14
  start-page: 193
  year: 2008
  end-page: 201
  ident: bib5
  article-title: Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance
  publication-title: Liver Transpl
  contributor:
    fullname: Jordan
– volume: 125
  start-page: 1695
  year: 2003
  end-page: 1704
  ident: bib4
  article-title: Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression
  publication-title: Gastroenterology
  contributor:
    fullname: Farrell
– volume: 258
  start-page: 274
  year: 2005
  end-page: 280
  ident: bib18
  article-title: Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis
  publication-title: J Intern Med
  contributor:
    fullname: Kaser
– volume: 27
  start-page: 1487
  year: 2004
  end-page: 1495
  ident: bib13
  article-title: Use and abuse of HOMA modeling
  publication-title: Diabetes Care
  contributor:
    fullname: Matthews
– volume: 165
  start-page: 1499
  year: 2004
  end-page: 1508
  ident: bib6
  article-title: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3
  publication-title: Am J Pathol
  contributor:
    fullname: Harada
– volume: 44
  start-page: 360
  year: 2006
  end-page: 367
  ident: bib14
  article-title: HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial
  publication-title: Hepatology
  contributor:
    fullname: Everhart
– volume: 113
  start-page: 40
  year: 2000
  end-page: 55
  ident: bib10
  article-title: Pathologic features of chronic hepatitis: a review and update
  publication-title: Am J Clin Pathol
  contributor:
    fullname: Ishak
– volume: 41
  start-page: 651
  year: 2003
  end-page: 656
  ident: bib11
  article-title: Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA
  publication-title: J Clin Microbiol
  contributor:
    fullname: Tanimoto
– volume: 25
  start-page: 472
  year: 2004
  end-page: 492
  ident: bib8
  article-title: Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
  publication-title: Control Clin Trials
  contributor:
    fullname: Lindsay
– volume: 63
  start-page: 315
  year: 2005
  end-page: 319
  ident: bib19
  article-title: Glucose intolerance caused by interferon therapy
  publication-title: Nippon Rinsho
  contributor:
    fullname: Omata
– volume: 41
  start-page: 132
  year: 2004
  end-page: 138
  ident: bib1
  article-title: Insulin resistance and insulin secretion in chronic hepatitis C virus infection
  publication-title: J Hepatol
  contributor:
    fullname: Akiyama
– volume: 49
  start-page: 831
  year: 2008
  end-page: 844
  ident: bib3
  article-title: Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis
  publication-title: J Hepatol
  contributor:
    fullname: El-Serag
– volume: 126
  start-page: 840
  year: 2004
  end-page: 848
  ident: bib7
  article-title: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance
  publication-title: Gastroenterology
  contributor:
    fullname: Miyoshi
– volume: 287
  start-page: E82
  year: 2004
  end-page: E89
  ident: bib17
  article-title: Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics
  publication-title: Am J Physiol Endocrinol Metab
  contributor:
    fullname: Manns
– volume: 60
  start-page: 760
  year: 2002
  end-page: 765
  ident: bib20
  article-title: Glucose intolerance induced by interferon therapy
  publication-title: Nippon Rinsho
  contributor:
    fullname: Sasaoka
– volume: 44
  start-page: 681
  year: 1977
  ident: 10.1016/j.cgh.2010.01.022_bib12
  article-title: Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jcem-44-4-681
  contributor:
    fullname: Hayashi
– volume: 41
  start-page: 132
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib1
  article-title: Insulin resistance and insulin secretion in chronic hepatitis C virus infection
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2004.03.020
  contributor:
    fullname: Narita
– volume: 14
  start-page: 193
  year: 2008
  ident: 10.1016/j.cgh.2010.01.022_bib5
  article-title: Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance
  publication-title: Liver Transpl
  doi: 10.1002/lt.21267
  contributor:
    fullname: Delgado-Borrego
– volume: 165
  start-page: 1499
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib6
  article-title: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3
  publication-title: Am J Pathol
  doi: 10.1016/S0002-9440(10)63408-6
  contributor:
    fullname: Kawaguchi
– volume: 113
  start-page: 40
  year: 2000
  ident: 10.1016/j.cgh.2010.01.022_bib10
  article-title: Pathologic features of chronic hepatitis: a review and update
  publication-title: Am J Clin Pathol
  doi: 10.1309/42D6-W7PL-FX0A-LBXF
  contributor:
    fullname: Ishak
– volume: 44
  start-page: 360
  year: 2006
  ident: 10.1016/j.cgh.2010.01.022_bib14
  article-title: HCV RNA detection by TMA during the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial
  publication-title: Hepatology
  doi: 10.1002/hep.21265
  contributor:
    fullname: Morishima
– volume: 49
  start-page: 831
  year: 2008
  ident: 10.1016/j.cgh.2010.01.022_bib3
  article-title: Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2008.08.006
  contributor:
    fullname: White
– volume: 77
  start-page: 703
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib2
  article-title: Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation
  publication-title: Transplantation
  doi: 10.1097/01.TP.0000114283.04840.3A
  contributor:
    fullname: Delgado-Borrego
– volume: 128
  start-page: 636
  year: 2005
  ident: 10.1016/j.cgh.2010.01.022_bib15
  article-title: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.12.049
  contributor:
    fullname: Romero-Gomez
– volume: 287
  start-page: E82
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib17
  article-title: Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00494.2003
  contributor:
    fullname: Tietge
– volume: 125
  start-page: 1695
  year: 2003
  ident: 10.1016/j.cgh.2010.01.022_bib4
  article-title: Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2003.08.032
  contributor:
    fullname: Hui
– volume: 60
  start-page: 760
  issue: Suppl 7
  year: 2002
  ident: 10.1016/j.cgh.2010.01.022_bib20
  article-title: Glucose intolerance induced by interferon therapy
  publication-title: Nippon Rinsho
  contributor:
    fullname: Sasaoka
– volume: 41
  start-page: 651
  year: 2003
  ident: 10.1016/j.cgh.2010.01.022_bib11
  article-title: Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.41.2.651-656.2003
  contributor:
    fullname: Hendricks
– volume: 258
  start-page: 274
  year: 2005
  ident: 10.1016/j.cgh.2010.01.022_bib18
  article-title: Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis
  publication-title: J Intern Med
  doi: 10.1111/j.1365-2796.2005.01543.x
  contributor:
    fullname: Kaser
– volume: 63
  start-page: 315
  issue: Suppl 2
  year: 2005
  ident: 10.1016/j.cgh.2010.01.022_bib19
  article-title: Glucose intolerance caused by interferon therapy
  publication-title: Nippon Rinsho
  contributor:
    fullname: Kanai
– volume: 27
  start-page: 1487
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib13
  article-title: Use and abuse of HOMA modeling
  publication-title: Diabetes Care
  doi: 10.2337/diacare.27.6.1487
  contributor:
    fullname: Wallace
– volume: 25
  start-page: 472
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib8
  article-title: Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
  publication-title: Control Clin Trials
  doi: 10.1016/j.cct.2004.08.003
  contributor:
    fullname: Lee
– volume: 126
  start-page: 840
  year: 2004
  ident: 10.1016/j.cgh.2010.01.022_bib7
  article-title: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2003.11.056
  contributor:
    fullname: Shintani
– volume: 5
  start-page: 245
  year: 2007
  ident: 10.1016/j.cgh.2010.01.022_bib9
  article-title: Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2006.11.002
  contributor:
    fullname: Lok
– volume: 102
  start-page: 570
  year: 2007
  ident: 10.1016/j.cgh.2010.01.022_bib16
  article-title: Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2006.01038.x
  contributor:
    fullname: Kawaguchi
SSID ssj0029497
Score 2.314871
Snippet Background & Aims Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a...
Hepatitis C virus (HCV) infection is associated with an increased prevalence of diabetes and insulin resistance (IR); whether this is a causal relationship has...
SourceID pubmedcentral
crossref
pubmed
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 458
SubjectTerms Adiponectin
Adult
Aged
Cirrhosis
Female
Gastroenterology and Hepatology
HALT-C
Hepatitis C - complications
Hepatitis C - drug therapy
HOMA
Humans
Insulin Resistance
Interferon
Interferon-alpha - therapeutic use
Longitudinal Studies
Male
Middle Aged
Polyethylene Glycols - therapeutic use
Recombinant Proteins
Ribavirin - therapeutic use
RNA, Viral - blood
Viral Load
Title Reduction of Insulin Resistance With Effective Clearance of Hepatitis C Infection: Results From the HALT-C Trial
URI https://www.clinicalkey.es/playcontent/1-s2.0-S1542356510001448
https://dx.doi.org/10.1016/j.cgh.2010.01.022
https://www.ncbi.nlm.nih.gov/pubmed/20156586
https://pubmed.ncbi.nlm.nih.gov/PMC2856733
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FVEJcEG_CS3vgROXIj7Vjc0sDKLSUQ0jV3lb2eu24gqSK3QP8LH4hM96H4_IslyiynYnX83n329lvZgl5KQTLGTARR7oiclgK0500wzVXAew9CWNZtBVvjj9G8xN2eBaeDQbfd1RLl002Ft9-mVfyP16FY-BXzJK9hmetUTgA38G_8Akehs9_8vEC664ayvdeq8oXskZOiC_sKQZZVX1iFAjNcIuI9gRG7yVqqZuq3sdOQimy1koeB3aaGiitTjyZTz8sHfAqNmiXy85MUmWZ1s12g8U9t11FpxXa78Xs38jPZZpvjLwiOMCNQUqVZvP1S2VRegjzYR2Wlduy2uzPx13IulQx8wMJLazskDJv6W5fo69DGWoVXocydO_LMLVAbR5huud4B4XhTlfLVMl3PWoz1af_NCCo2MT5WJQrrePDGq1-N_qZFf8rg6KVKhoV3DkHExxNcNfjYOIG2cPii2xI9qZHi9MjO81PmNrSxzTGrKW3qsIr9_FXNtRX6u5Qn-UdclvPWehUAfAuGcj1PXLzWKsy7pMLi0O6KajGIe1wSBGH1OKQWhzi5RaHdEYtDl9TjUKKKKSAQqpQSFsUPiAn794uZ3NH7-ThCGDYjTNJgwyoaBHnYR77iYyKuBBenjNR5AFSyrTw0pBJlmXQs7leAb1H4iZxAbNjWbhB8JAM15u1fEyoL0QONl0ZBRmTbp4mkchEmEVITKOQjcgr80T5hSrYwn_rwxGZmGfOTSYyjJ2y1i95zT1e-9zln9Cb6EyvDSqweESY_aXmqoqDckDen_7wkXKovTcfaxmEcQS30nO1vQDrv_fPrKtVWwfej8NoEgRPrtPip-RW9-Y9I8NmeymfA61ushcaxz8AdT3OOw
link.rule.ids 230,314,780,784,885,27924,27925
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+of+Insulin+Resistance+With+Effective+Clearance+of+Hepatitis+C+Infection%3A+Results+From+the+HALT-C+Trial&rft.jtitle=Clinical+gastroenterology+and+hepatology&rft.au=Delgado%E2%80%93Borrego%2C+Aymin&rft.au=Jordan%2C+Sergio+H.&rft.au=Negre%2C+Betania&rft.au=Healey%2C+David&rft.date=2010-05-01&rft.issn=1542-3565&rft.volume=8&rft.issue=5&rft.spage=458&rft.epage=462&rft_id=info:doi/10.1016%2Fj.cgh.2010.01.022&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_cgh_2010_01_022
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F15423565%2FS1542356510X00040%2Fcov150h.gif